-
APA. The America psychiatric association practice guideline for the treatment of patients with borderline personality disorder. 2023. https://www.psychiatry.org/getmedia/3ac9a443-4590-47e6-ad9b-0b2d1cff4d53/APA-Borderline-Personality-Disorder-Practice-Guideline-Under-Copyediting.pdf. Accessed 20 June 2024.
pubmed_reference_list
-
American Psychiatric Association. APA. Diagnostic and statistical manual of mental disorders. 5th Edn. 2013.
pubmed_reference_list
-
Videler AC, Hutsebaut J, Schulkens JEM, Sobczak S, van Alphen SPJ. A life span perspective on borderline personality disorder. Curr Psychiatry Rep. 2019;21:51.
pubmed_reference_list
-
Wagner T, Assmann N, Köhne S, Schaich A, Alvarez-Fischer D, Borgwardt S, et al. The societal cost of treatment-seeking patients with borderline personality disorder in Germany. Eur Arch Psychiatry Clin Neurosci. 2022;272:741–52.
pubmed_reference_list
-
DiBenedetti D, Kosa K, Waters HC, Oberdhan D. Understanding patients’ experiences with borderline personality disorder: qualitative interviews. Neuropsychiatr Dis Treat. 2023;19:2115–25.
pubmed_reference_list
-
Fok ML, Hayes RD, Chang CK, Stewart R, Callard FJ, Moran P. Life expectancy at birth and all-cause mortality among people with personality disorder. J Psychosom Res. 2012;73:104–07.
pubmed_reference_list
-
IsHak WW, Elbau I, Ismail A, Delaloye S, Ha K, Bolotaulo NI, et al. Quality of life in borderline personality disorder. Harv Rev Psychiatry. 2013;21:138–50.
pubmed_reference_list
-
Sveen CA, Pedersen G, Ulvestad DA, Zahl KE, Wilberg T, Kvarstein EH. Societal costs of personality disorders among treatment-seeking patients in Norway: the relative contribution of specific DSM-5 categories. Eur Arch Psychiatry Clin Neurosci. 2024;274:139–49.
pubmed_reference_list
-
Hastrup LH, Jennum P, Ibsen R, Kjellberg J, Simonsen E. Societal costs of borderline personality disorders: a matched-controlled nationwide study of patients and spouses. Acta Psychiatr Scand. 2019;140:458–67.
pubmed_reference_list
-
Paris J. Differential diagnosis of borderline personality disorder. Psychiatr Clin N Am. 2018;41:575–82.
pubmed_reference_list
-
Tomko RL, Trull TJ, Wood PK, Sher KJ. Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning. J Pers Disord. 2014;28:734–50.
pubmed_reference_list
-
Simonsen S, Bateman A, Bohus M, Dalewijk HJ, Doering S, Kaera A, et al. European guidelines for personality disorders: past, present and future. Borderline Pers Disord Emot Dysregul. 2019;6:9.
pubmed_reference_list
-
Tyrer P, Silk KR. A comparison of UK and US guidelines for drug treatment in borderline personality disorder. Int Rev Psychiatry. 2011;23:388–94.
pubmed_reference_list
-
Paton C, Crawford MJ, Bhatti SF, Patel MX, Barnes TR. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry. 2015;76:e512–8.
pubmed_reference_list
-
Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American psychiatric association practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2024;181:1024–28.
pubmed_reference_list
-
Del Casale A, Bonanni L, Bargagna P, Novelli F, Fiaschè F, Paolini M, et al. Current clinical psychopharmacology in borderline personality disorder. Curr Neuropharmacol. 2021;19:1760–79.
pubmed_reference_list
-
Bohus M, Stoffers-Winterling J, Sharp C, Krause-Utz A, Schmahl C, Lieb K. Borderline personality disorder. Lancet. 2021;398:1528–40.
pubmed_reference_list
-
Ning AY, Theodoros T, Harris K, Isoardi KZ. Overdose and off-label psychotropic prescribing in patients with borderline personality disorder: a retrospective series. Australas Psychiatry. 2023;31:195–200.
pubmed_reference_list
-
NICE. Borderline personality disorder: recognition and management. 2009. https://www.nice.org.uk/guidance/cg78. Accessed 25 Jun 2024.
pubmed_reference_list
-
Gartlehner G, Crotty K, Kennedy S, Edlund MJ, Ali R, Siddiqui M, et al. Pharmacological treatments for borderline personality disorder: a systematic review and meta-analysis. CNS Drugs. 2021;35:1053–67.
pubmed_reference_list
-
Magni LR, Ferrari C, Barlati S, Ridolfi ME, Prunetti E, Vanni G, et al. Psychopharmacological treatment in borderline personality disorder: a pilot observational study in a real-world setting. Psychiatry Res. 2021;295:113556.
pubmed_reference_list
-
Stoffers-Winterling JM, Storebø OJ, Pereira Ribeiro J, Kongerslev MT, Völlm BA, Mattivi JT, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2022.
pubmed_reference_list
-
Patel R, Wee SN, Ramaswamy R, Thadani S, Tandi J, Garg R, et al. NeuroBlu, an electronic health record (EHR) trusted research environment (TRE) to support mental healthcare analytics with real-world data. BMJ Open. 2022;12:e057227.
pubmed_reference_list
-
A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 1358894 once daily over 12 week treatment period in patients with borderline personality disorder [internet]. 2020. [cited 22 Jul 2025]. Available from: https://clinicaltrials.gov/study/NCT04566601.
pubmed_reference_list
-
Mukherjee SS, Yu J, Won Y, McClay MJ, Wang L, Rush AJ, et al. Natural language processing-based quantification of the mental state of psychiatric patients. Comput Psychiatry. 2020;4:76–106.
pubmed_reference_list
-
Starcevic V, Janca A. Pharmacotherapy of borderline personality disorder: replacing confusion with prudent pragmatism. Curr Opin Psychiatry. 2018;31:69–73.
pubmed_reference_list
-
Di Leone F, Steingrimsson S, Carlsen HK, Liljedahl SI, Sand P. Trends in pharmacological prescriptions and polypharmacy for personality disorders: a 10-year cross-sectional analysis of naturalistic data. BMC Psychiatry. 2025;25:314.
pubmed_reference_list
-
Tennant M, Frampton C, Mulder R, Beaglehole B. Polypharmacy in the treatment of people diagnosed with borderline personality disorder: repeated cross-sectional study using New Zealand’s national databases. BJPsych Open. 2023;9:e200.
pubmed_reference_list
-
Bridler R, Häberle A, Müller ST, Cattapan K, Grohmann R, Toto S, et al. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol. 2015;25:763–72.
pubmed_reference_list
-
Riffer F, Farkas M, Streibl L, Kaiser E, Sprung M. Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines. Int J Psychiatry Clin Pract. 2019;23:178–88.
pubmed_reference_list
-
Curry DE, Richards BL. A brief review of Quetiapine. Am J Psychiatry Residents’ J. 2022;18:20–22.
pubmed_reference_list
-
APA. Practice guideline for the treatment of patients with borderline personality disorder. APA; 2001.
pubmed_reference_list
-
National Collaborating Centre for Mental H. National institute for health and care excellence: guidelines. Borderline personality disorder: treatment and management. Leicester (UK): British Psychological Society; 2009.
pubmed_reference_list
-
Haw C, Stubbs J. Medication for borderline personality disorder: a survey at a secure hospital. Int J Psychiatry Clil Pract. 2011;15:270–74.
pubmed_reference_list
-
Zanarini MC, Frankenburg FR, Khera GS, Bleichmar J. Treatment histories of borderline inpatients. Compr Psychiatry. 2001;42:144–50.
pubmed_reference_list
-
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:230.
pubmed_reference_list
-
Zanarini MC, Frankenburg FR, Reich DB, Harned AL, Fitzmaurice GM. Rates of psychotropic medication use reported by borderline patients and Axis II comparison subjects over 16 years of prospective follow-up. J Clin Psychopharmacol. 2015;35:63–67.
pubmed_reference_list
-
Guilé JM, Boissel L, Alaux-Cantin S, De La Rivière SG. Borderline personality disorder in adolescents: prevalence, diagnosis, and treatment strategies. Adolesc Health Med Ther. 2018;9:199–210.
pubmed_reference_list
-
APA. Practice guideline for the treatment of patients with borderline personality disorder. Am Psychiatric Assoc Am J Psychiatry. 2001;158:1–52.
pubmed_reference_list
-
Kadiyala S, Chenoweth M, Watanabe JH. Off-label policy through the lens of trazodone usage and spending in the United States. Health Aff (Millwood) Scholar. 2025;3.
pubmed_reference_list
-
Pardossi S, Cuomo A, Koukouna D, Pinzi M, Firenzuoli B, Fagiolini A. Methylphenidate in borderline personality disorder: assessing its therapeutic potential and limitations. Life (Basel). 2025;15.
pubmed_reference_list
-
Leichsenring F, Fonagy P, Heim N, Kernberg OF, Leweke F, Luyten P, et al. Borderline personality disorder: a comprehensive review of diagnosis and clinical presentation, etiology, treatment, and current controversies. World Psychiatry. 2024;23:4–25.
pubmed_reference_list
-
Cloitre M, Garvert DW, Weiss B, Carlson EB, Distinguishing BRA, PTSD. Complex PTSD, and borderline personality disorder: a latent class analysis. Eur J Psychotraumatol. 2014;5.
pubmed_reference_list
-
Weiner L, Perroud N, Weibel S. Attention deficit hyperactivity disorder and borderline personality disorder in adults: a review of their links and risks. Neuropsychiatr Dis Treat. 2019;15:3115–29.
pubmed_reference_list
-
Lorenzi G, Baldwin DS. How should non-prescribed use of gabapentinoids be reduced in psychiatric practice? Hum Psychopharmacol Clin Exp. 2025;40:e70010.
pubmed_reference_list
-
Fournier J, Barret L, Khouri C, Naudet F, Boussageon R, Roustit M. The evidence base of the 10 most prescribed drugs in England, France, and the United States: a scoping review. J Clin Epidemiol. 2024;174:111478.
pubmed_reference_list